Dr. David Kuninger leads research, development and commercialization of media systems for stem cell culture & differentiation, neurobiology, and
cell therapy applications at Thermo Fisher Scientific as part of the Cell Biology business based in Frederick MD..
Manager,
Cell Therapy Application Support, Fresenius Kabi, USA Alaina manages application support for the Lovo Cell Processing System at Fresnius Kabi where she has worked since 2014.
Human mesenchymal stem cells (hMSCs) are currently the most common adult stem cell type used for
cell therapy applications due to their regenerative properties and ability to differentiate into multiple cell lineages (adipocyte, chondro ¬ cyte, and osteocyte).
The Bulte Lab has developed methods to label cells magnetically using tiny superparamagnetic iron oxide nanoparticles in order to make them visible by magnetic resonance imaging; this technology has now been introduced in the clinic for
several cell therapy applications.
In parallel to
this cell therapy application, keratynocytes and melanocytes derived from pluripotent stem cells will be used for pathological modelling of genodermatoses allowing identification of new disease - specific pharmacological treatments